Axonics (AXNX) Q2 2024 earnings summary

Executive summary

• Net revenue for Q2 2024 was $114.6M, up 23% year-over-year, driven by increased U.S. product sales and new account onboarding.

• Gross margin improved to 77.8% from 75.6% in Q2 2023, reflecting higher sales volumes and favorable product mix.

• Net income for Q2 2024 was $6.9M, reversing a net loss of $7.3M in Q2 2023.

• Operating expenses rose to $85.5M due to higher personnel, legal, advertising, and R&D costs.

• The pending merger with Boston Scientific remains under FTC review, with stockholder approval obtained.

Financial highlights

• Q2 2024 net revenue: $114.6M (+23% YoY); six months: $206.0M (+25.9% YoY).

• Q2 2024 gross profit: $89.1M; gross margin: 77.8% (vs. 75.6% prior year).

• Q2 2024 net income: $6.9M (EPS $0.14 basic, $0.13 diluted); six-month net loss: $12.2M.

• Operating expenses for Q2 2024: $85.5M, up from $82.3M in Q2 2023.

• Cash, cash equivalents, short-term investments, and restricted cash totaled $362.0M as of June 30, 2024.

Outlook and guidance

• Management expects existing liquidity to fund operations for at least the next 12 months.

• Ongoing investments in sales, marketing, and R&D are anticipated as the company continues to commercialize and expand internationally.

• Management remains confident in continued market expansion and leadership, supported by innovation and clinical support.

• Anticipates further global impact as part of Boston Scientific following the pending merger.

• No material changes to risk factors or forward-looking statements since the last annual report.